Blood tests may reveal hidden cancer clues
NCT ID NCT05088395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting blood samples from up to 2050 cancer patients to look for tiny pieces of tumors, called biomarkers, in the blood. The goal is to see how often these markers can be detected. Participation does not change standard cancer care or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 2,050 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient treated for cancer at one of the participating center * 18 years old or higher * Signed informed consent form * Patient not deprived of their liberty or under guardianship (including temporary guardianship) * Patient covered by social security scheme * Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up * Other additional criteria will be defined (defining tumor type and clinical setting), by cohort If a biopsy tumor sample is to be taken: * Tumor considered as accessible by biopsy (at the investigator's discretion). * Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion). * No anticoagulant or antiaggregant treatment for the biopsy. Exclusion Criteria : Pregnant and/or breast-feeding women depending on cohort.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut Curie
RECRUITINGParis, 75005, France
-
Institut Curie
RECRUITINGSaint-Cloud, 92210, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?